Healthcare Industry News: CoreValve
News Release - October 24, 2007
CoreValve's 18-French ReValving(TM) System for percutaneous aortic valve replacement (PAVR) demonstrated 'live' at TCT 2007
The percutaneous ReValving(TM) procedure was used to non-surgically implant a new aortic bioprosthesis over the diseased heart valve of a 74-year-old female patient who was at high risk for open-heart surgeryIRVINE, Calif.--(HSMN NewsFeed)--CoreValve (www.CoreValve.com) announced today that its third-generation, proprietary aortic heart valve was implanted successfully — non-surgically — in a ‘high-risk’ patient suffering from Chronic Obstructive Pulmonary Disease (COPD) using CoreValve’s percutaneous, 18-French ReValving™ System, at the ‘TCT 2007’ (Transcatheter Cardiovascular Therapeutics) scientific symposium in Washington, D.C. Sponsored by the Cardiovascular Research Foundation, TCT is one of the largest international vascular medicine meetings in the world. Dr. Eberhard Grube and Dr. Ulrich Gerckens of the HELIOS Heart Center, Siegburg, Germany, performed the ReValving™ procedure ‘live’ via satellite television from their hospital’s ‘cath lab’ for an audience comprised of international cardiologists, cardiovascular surgeons and industry executives.
“This was the 158th ReValving™ procedure within the scope of our post-CE Mark Expanded Evaluation registry. When combined with the results of 191 previous cases of the feasibility, safety and efficacy trials, it demonstrates that interventional cardiology treatment of structural heart disease is no longer just a hope for the future but a reality today that provides a new treatment option for high-risk and inoperable patients,” said Jacques Séguin, M.D., Ph.D., Chairman, CEO and Founder of CoreValve.
About CoreValve
Founded in 2001, privately held CoreValve—which is headquartered in Irvine, California—has developed a proprietary delivery system and tissue heart valve for percutaneous heart valve replacement. Based on a novel catheter-and-self-expanding-frame approach on a beating heart, the proprietary CoreValve ReValving™ System procedure is intended to avoid open-heart surgery. It can be performed in a cardiac “cath lab” just like angioplasty and stenting, which may result in less trauma to the patient and may offer substantial cost-savings to the healthcare system. For more information about CoreValve, visit the Company’s Web site at www.CoreValve.com.
(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)
Source: CoreValve
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
